Two systematic reviews of randomized placebo controlled trials revealed anti-TNF antibody therapies as used to treat auto-immune diseases have been associated with a significantly increased risk of infections ranging from 20 (any infection) to 250% (tuberculosis; Minozzi et al., 2016). This evidence concerns the gene TNF and infection.